Down 34.5% in One Month, Genfit Stock Continues to Decline This Friday
The Lille-based biotech company specializing in hepatic and metabolic diseases remains under pressure this Friday. The decline occurs in a rising Paris market, which amplifies the gap with the index. The stock remains below its main moving averages, approaching a monitored support level.
A Decline of 2.3% Against the Grain of a Rising SBF 120
Genfit is down 2.33% to €9.22 in early afternoon, while the SBF 120 advances 0.42%. The stock is among the index's biggest losers, in the wake of a very difficult month: the security loses nearly 35% over this period, after having nonetheless gained nearly 2% over the week. Market conditions remain marked by tension in French debt, with a 10-year OAT at 4.90% according to the latest reading from the Banque de France on October 1, 2026.
Declared net short positions reach 2.07% of capital, distributed among three funds, according to the disclosures reviewed. This accumulation appeared within 30 days, reflecting selling pressure that has recently established itself without being massive. This point is being monitored without being overinterpreted.
A Stock Below Its Three Moving Averages, Facing a Support Level at €8.92
The price is below the 20-day MA (gap of 18.84%), the 50-day MA (28.30%) and the 200-day MA (3.05%). The gap with the 200-day MA, at €9.51, is the tightest of the three: the stock has remained below this line since its recent decline, and the RSI at 34 signals a configuration near oversold territory. The support at €8.92 is located less than 4% from the current price.
On the analyst side, CIC Market Solutions maintained its buy rating on October 1 with a price target of €20, representing a potential upside of more than 100% from today's price. The €8.92 level is the nearest technical threshold.
